RecruitingNot ApplicableNCT06587698

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

Sponsor

Peking University Third Hospital

Enrollment

300 participants

Start Date

Aug 21, 2024

Study Type

INTERVENTIONAL

Conditions

Polycystic Ovarian Syndrome

Summary

This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research

Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two treatments — sitagliptin (a diabetes medication) and BeiDouGen capsule (a traditional Chinese herbal medicine) — for women with polycystic ovary syndrome (PCOS) who are trying to become pregnant. Both drugs may help regulate ovulation and improve pregnancy outcomes. **You may be eligible if...** - You are a female between 20 and 40 years old who wants to conceive or is being treated for infertility - You have been diagnosed with PCOS based on Rotterdam criteria (irregular ovulation, elevated male hormones, or polycystic ovaries on ultrasound — meeting at least 2 of 3 criteria) - You have insulin resistance or elevated insulin levels **You may NOT be eligible if...** - You do not have PCOS - You are outside the 20–40 age range - You have other causes of infertility not related to PCOS - You have contraindications to either study medication - You are already pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.